KameleonPharma
ActiveKameleonPharma has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €57k and a net result of €18k. Equity is growing by ~20.9% per year across the filed fiscal years. Its solvency ranks better than 88% of 18173 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Checked score
Score 2025
92
/ 100
Excellent
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100▲+20
Solvency100▲+3
Growth78=
Track record100
Bankruptcy probability, 12 months
0.7%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €5k at 30 days acceptable
Liquidity ample (current ratio 5.74 against 4.16 in 2024; short-term debt: 15.2% and cash: 65.4% of total assets), and 18.6% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
81.4%
Return on assets
26%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
2 d early
2024
31 d early
2023
34 d early
2022
6 d early
2021
4 d early
2020
8 d early
2019
2 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€57k▲ 47.0%
2024 · €39k
2018: €10k
2019: €15k
2020: €19k
2021: €19k
2022: €28k
2023: €34k
2024: €39k
2018 → 2025
Total assets
€70k▲ 30.5%
2024 · €54k
2018: €23k
2019: €25k
2020: €26k
2021: €29k
2022: €49k
2023: €53k
2024: €54k
2018 → 2025
Net result
€18k▲ 279%
2024 · €5k
2018: €1k
2019: €5k
2020: €4k
2021: €204
2022: €9k
2023: €6k
2024: €5k
2018 → 2025
Working capital
€51k▲ 66.1%
2024 · €30k
2018: €10k
2019: €15k
2020: €19k
2021: €18k
2022: €25k
2023: €24k
2024: €30k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€19k-€28k▲ 47.4%€34k▲ 20.0%€39k▲ 14.2%€57k▲ 47.0%
Operating result€3k-€14k▲ 349%€11k▼ 22.5%€9k▼ 18.0%€27k▲ 204%
Net result€204-€9k▲ 4,373%€6k▼ 37.8%€5k▼ 15.0%€18k▲ 279%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 204% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €70k
Fixed assets
€9k▼ 34.5%
Current assets
€61k▲ 52.8%
Equity and liabilities €70k
Equity
€57k▲ 47.0%
Debt
€13k▼ 12.5%
The debt ratio falls from 27.7% to 18.6%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€30k▲
2024 · €13k
Cash flow
€21k▲
2024 · €9k
Solvency
81.4%▲
2024 · 72.3%
Current ratio
5.74▲
2024 · 4.16
Quick ratio
5.60▲
2024 · 3.80
Debt / equity
0.23▼
2024 · 0.38
ROE
32.0%▲
2024 · 12.4%
ROA
26.0%▲
2024 · 9.0%
Interest coverage
65.95▲
2024 · 18.91
Debt
€13k▼
2024 · €15k
Debt ≤ 1 year
€11k▲
2024 · €10k
Debt > 1 year
€2k▼
2024 · €5k
Income taxes
€9k▲
2024 · €4k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€54k€70k▲
Fixed assets21/28€14k€9k▼
Intangible fixed assets21€575-
Tangible fixed assets22/27€13k€9k▼
Land and buildings22€7k€7k▼
Plant, machinery and equipment23€6k€2k▼
Current assets29/58€40k€61k▲
Stocks and contracts in progress3€3k€2k▼
Stocks30/36€3k€2k▼
Amounts receivable within one year40/41€10k€3k▼
Trade receivables40€10k-
Other amounts receivable41€232€3k▲
Cash at bank and in hand54/58€26k€46k▲
Deferred charges and accrued income490/1€1k€11k▲
Equity and liabilities
Total equity and liabilities10/49€54k€70k▲
Equity10/15€39k€57k▲
Contributions10/11€6k€6k=
Reserves13€33k€51k▲
Distributable reserves133€33k€51k▲
Amounts payable17/49€15k€13k▼
Amounts payable after more than one year17€5k€2k▼
Financial debts170/4€5k€2k▼
Amounts payable within one year42/48€10k€11k▲
Current portion of amounts payable after more than one year42€3k€3k▲
Trade debts44€223€1k▲
Suppliers440/4€223€1k▲
Taxes, remuneration and social security45€5k€7k▲
Taxes450/3€5k€7k▲
Other amounts payable47/48€1k-
Accrued charges and deferred income492/3€139-
Income statement
Code20242025
Non-recurring operating income76A-€1k
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€4k€3k▼
Other operating charges640/8€2k€2k▼
Gross operating margin9900€15k€32k▲
Operating profit (loss)9901€9k€27k▲
Financial income75/76B€125€1▼
Recurring financial income75€125€1▼
Financial charges65/66B€676€458▼
Recurring financial charges65€676€458▼
Profit (loss) for the period before taxes9903€8k€27k▲
Income taxes67/77€4k€9k▲
Profit (loss) for the period9904€5k€18k▲
Profit (loss) for the period to be appropriated9905€5k€18k▲
Appropriation of the result
Profit (loss) to be appropriated9906€5k€18k▲
Transfer to equity691/2€5k€18k▲
To other reserves6921€5k€18k▲
The notes to these accounts (11 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
29-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2018net €18k ▲279%
Operating result €27k, net result €18k, both a record.
30-06
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
27-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
25-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
27-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
31-12
Financial
Weakest financial yearnet €204 ▼95.3%
Net result drops to €204, the lowest in the series; recovery starts the following year.
23-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
29-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
12-06
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
31-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Wellen · 1 establishment unit since 2017
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Widdingenstraat 33830 WellenGround area
409 m²
Building footprint
146 m²
Volume, LiDAR
717 m³
Parcel 73004B0006/00F002, Flanders · tallest building 9.3 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
KameleonPharma
since 20172.259.775.643
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 73004B0006/00F002 | Flanders | 409 m² | 1 · 146 m² | 9.3 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2025 · 1 entry · 569 EUR awarded · 569 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 569 EUR | 569 EUR |
Schemes
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Similar companies · same sector, comparable size
PHARMACIE MON ANGE
BE 0878.040.238
Etterbeek · Eq €57k
Benisa BV
BE 0731.796.704
Dilsen-Stokkem · Eq €57k
EVRAS
BE 0417.723.174
Frameries · Eq €57k
HCL PHARMA
BE 0649.663.933
Walcourt · Eq €57k
EL MANAGEMENT
BE 1003.039.287
Waremme · Eq €57k
Of 5,223 companies in sector 47730 we hold annual accounts for 3,862. 2,916 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded17-11-2016
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
23410Manufacture of ceramic household and ornamental articles
23450Manufacture of other non-metallic mineral products
74104Other professional, scientific and technical activities
74130Interior design
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.